GoodRx Holdings, Inc. Class A Common Stock (GDRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XFRA 
GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope
GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating.
GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript
GoodRx Holdings, Inc. (GDRX) Q2 2026 Earnings Call Transcript
GoodRx Q2 Earnings Call Highlights
GoodRx NASDAQ: GDRX reported second-quarter 2026 revenue of $200.4 million and adjusted EBITDA of $63.7 million, representing a 31.8% adjusted EBITDA margin, as growth in its Pharma Direct and subscription businesses offset pressure in prescription transaction revenue.
GoodRx and Oscar Health Tout Tech as Consumer Needs Change
The latest earnings from Oscar Health and GoodRx show both companies dealing with a changing customer base. The former company reported half-year earnings Thursday (Aug. 6) showing record profitability for the first six months of 2026, with revenues surging 70% to $4.9 billion.
GoodRx Holdings, Inc. (GDRX) Q2 Earnings Match Estimates
GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.09 per share a year ago.
GoodRx (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
GoodRx (GDRX) Upgraded to Buy: What Does It Mean for the Stock?
GoodRx (GDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GDRX or HQY: Which Is the Better Value Stock Right Now?
Investors interested in Medical Services stocks are likely familiar with GoodRx Holdings, Inc. (GDRX) and HealthEquity (HQY). But which of these two stocks offers value investors a better bang for their buck right now?
Is GoodRx (GDRX) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade)
GoodRx Holdings, Inc. faces ongoing revenue and margin pressure as its legacy business declines and Pharma Direct grows but with lower profitability. GDRX's Q1 results showed a 4% Y/Y revenue drop and EBITDA margin compression to 18.5%, with management expecting continued legacy erosion through 2026. Valuation sensitivity is highest to margin assumptions; the base DCF value is $2.49/share, near the current price, with scenario analysis skewed toward downside risk.
GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript
GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript
Big Pharma Runs Its Checkout Counter Through GoodRx
Out-of-pocket drug costs are rising for millions of Americans. Coverage gaps are widening.
